- Home
- STTK vs CRVS Comparison
STTK vs CRVS Comparison
Compare STTK & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- CRVS
- Stock Information
- Founded
- STTK 2016
- CRVS 2014
- Country
- STTK United States
- CRVS United States
- Employees
- STTK N/A
- CRVS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- STTK Health Care
- CRVS Health Care
- Exchange
- STTK Nasdaq
- CRVS Nasdaq
- Market Cap
- STTK 173.6M
- CRVS 161.4M
- IPO Year
- STTK 2020
- CRVS 2016
- Fundamental
- Price
- STTK $3.69
- CRVS $5.78
- Analyst Decision
- STTK Strong Buy
- CRVS Buy
- Analyst Count
- STTK 3
- CRVS 4
- Target Price
- STTK $10.67
- CRVS $10.83
- AVG Volume (30 Days)
- STTK 122.7K
- CRVS 468.1K
- Earning Date
- STTK 11-07-2024
- CRVS 11-05-2024
- Dividend Yield
- STTK N/A
- CRVS N/A
- EPS Growth
- STTK N/A
- CRVS N/A
- EPS
- STTK N/A
- CRVS N/A
- Revenue
- STTK $4,123,999.00
- CRVS N/A
- Revenue This Year
- STTK $164.45
- CRVS N/A
- Revenue Next Year
- STTK N/A
- CRVS N/A
- P/E Ratio
- STTK N/A
- CRVS N/A
- Revenue Growth
- STTK 380.09
- CRVS N/A
- 52 Week Low
- STTK $1.33
- CRVS $1.05
- 52 Week High
- STTK $11.76
- CRVS $6.15
- Technical
- Relative Strength Index (RSI)
- STTK 51.49
- CRVS 79.19
- Support Level
- STTK $3.63
- CRVS $3.90
- Resistance Level
- STTK $3.94
- CRVS $4.75
- Average True Range (ATR)
- STTK 0.23
- CRVS 0.40
- MACD
- STTK 0.06
- CRVS 0.09
- Stochastic Oscillator
- STTK 56.14
- CRVS 83.56
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).